Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban

Novo Nordisk faces a critical 'show me' moment for its weight-loss drug Wegovy as a U.S. ban on compounded versions, effective May 22, has spurred a 33% increase in new prescriptions, narrowing its market share gap with Eli Lilly's Zepbound. Despite this initial rebound, investor confidence remains tempered following Novo's recent sales forecast cut and CEO departure, placing significant pressure on the company to demonstrate sustained, robust growth in its upcoming Q2 earnings report on August 6 to restore market trust.

Analysis

Novo Nordisk is in a critical 'show me' phase as it attempts to restore market confidence in its weight-loss drug, Wegovy. While a U.S. Food and Drug Administration ban on compounded versions has spurred a tangible 33% increase in new prescriptions since May 22, reaching 181,200 in the week ended July 18, significant investor skepticism persists. This nascent recovery has narrowed the prescription gap with Eli Lilly's Zepbound from nearly 175,000 to approximately 133,000. However, this positive momentum is weighed against a backdrop of a recent full-year guidance cut in May, which lowered sales growth forecasts to 13-21%, the surprise exit of its CEO, and a stock price trading nearly 60% below its 2024 peak. The upcoming August 6 earnings report is a pivotal event, with analysts divided on whether the company will reaffirm or trim its guidance. Uncertainty also surrounds the impact of the new NovoCare direct-to-consumer platform, which could drive volume but potentially at lower initial price points, further complicating the near-term outlook.

Key Decisions for Investors

• Investors should treat the upcoming August 6 earnings report as a key catalyst, focusing on whether management reaffirms its current guidance or makes further downward revisions as some analysts anticipate.
• Given the 'exceptionally weak' sentiment and the stock's significant decline, a positive earnings surprise or strong guidance could present a contrarian opportunity, but downside risk remains high if results disappoint.
• Monitor weekly IQVIA prescription data to assess if Wegovy's market share recapture from Eli Lilly's Zepbound is a sustainable trend following the ban on compounded alternatives.
• Closely scrutinize any company commentary on the performance and pricing strategy of the NovoCare direct-to-consumer channel, as this will be a critical factor for future revenue quality and margin analysis.